Factors associated with poor T-cell reconstitution (CD4+ T cells <600 cells/mm3) at 2 years post-HCT
| Variable . | OR (95% CI) . | P* . | aOR (95% CI) . | P* . |
|---|---|---|---|---|
| Native American† | 6.0 (3.6-9.9) | <.0001 | ||
| Omenn syndrome | 0.5 (0.3-1.0) | .05 | ||
| Ulcers | 4.5 (2.4-8.5) | <.0001 | 8.4 (3.0-23.4) | <.0001 |
| No myeloablative conditioning | 3.5 (2.3-5.4) | <.0001 | 3.0 (2.0-4.5) | <.0001 |
| Any alkylator therapy‡ | 0.4 (0.3-0.7) | .001 | ||
| No myeloid chimerism (recipient) | 7.4 (1.8-30.6) | .005 | 6.3 (1.9-20.7) | .002 |
| IVIG requirement | 4.7 (1.5-15.0) | .01 | ||
| CD4+ T cells at 1 y post-HCT | 12.4 (2.4-65.0) | .003 |
| Variable . | OR (95% CI) . | P* . | aOR (95% CI) . | P* . |
|---|---|---|---|---|
| Native American† | 6.0 (3.6-9.9) | <.0001 | ||
| Omenn syndrome | 0.5 (0.3-1.0) | .05 | ||
| Ulcers | 4.5 (2.4-8.5) | <.0001 | 8.4 (3.0-23.4) | <.0001 |
| No myeloablative conditioning | 3.5 (2.3-5.4) | <.0001 | 3.0 (2.0-4.5) | <.0001 |
| Any alkylator therapy‡ | 0.4 (0.3-0.7) | .001 | ||
| No myeloid chimerism (recipient) | 7.4 (1.8-30.6) | .005 | 6.3 (1.9-20.7) | .002 |
| IVIG requirement | 4.7 (1.5-15.0) | .01 | ||
| CD4+ T cells at 1 y post-HCT | 12.4 (2.4-65.0) | .003 |
n = 76 patients (still alive after 2 y post-HCT). Only significant results in univariate analysis are shown. Patients were clustered using a group variable to take into account the practice variations between centers.
aOR, adjusted odds ratio.
P values are referring to univariate analysis (left column) and multivariate analysis (right column), respectively.
Variable not kept in the multivariate model because of colinearity with ulcers.
Category analyzing all conditioning regimens containing the following alkylating agents including both immunosuppressive and stem cell–toxic regimens: busulfan, treosulfan, thiothepa, melphalan, cyclophosphamide.